All entries on Merck KGaA across all areas, newest first. tag:eurotrack.ai,2026:en:en/companies/merck-kgaa 2026-11-03T06:00:00Z Eurotrack tag:eurotrack.ai,2026:b8aaab14:en 2026-11-03T06:00:00Z

Basel-based contract manufacturer Lonza has signed an agreement to acquire five US development and manufacturing sites from Merck KGaA, with around 1,100 employees transferring to Lonza. The sites cover bioconjugates such as antibody-drug conjugates and viral vectors; Lonza goes from four to nine US sites and to more than 6,000 employees there. The enterprise value is in the low to mid triple-digit millions of Swiss francs (Lonza, ad hoc announcement, 3 November 2026). — Source: https://www.finanznachrichten.de/nachrichten-2026-11/70013589-adhoc-lonza-group-ag-lonza-signs-agreement-to-acquire-us-cdmo-network-from-merck-kgaa-darmstadt-germany-and-significantly-expands-its-us-presence-023.htm

tag:eurotrack.ai,2026:6153f9fe:en 2026-10-19T06:00:00Z

Merck KGaA is buying UK RNA specialist Silence Therapeutics for US$20 per depositary share in cash, 130% above the closing price on 16 October 2026; the deal is worth about US$1.3bn. Closing is expected in Q1 2027 (KSL citing Reuters, 19 October 2026; second source: Pulse 2.0, 19 October 2026). — Sources: https://www.ksl.com/article/51638103/germanys-merck-buys-silence-therapeutics-for-13-billion · https://pulse2.com/merck-to-acquire-silence-therapeutics-for-about-1-3-billion/

tag:eurotrack.ai,2026:3c4db44e:en 2026-08-17T06:00:00Z

Merck KGaA (Darmstadt) had agreed on 25 June 2026 to acquire US life-science company Bio-Techne (Minneapolis) for USD 73 per share (enterprise value around USD 11.3 billion / EUR 10 billion), strengthening its cell and gene therapy and precision diagnostics business. Germany's Federal Cartel Office cleared the merger on 17 August 2026 'after a short but intensive review'; clearances in other jurisdictions are still pending, with completion expected late 2026 or early 2027. The June announcement had not been recorded in the tracker; this entry is the authoritative one. Update (23 September 2026): The US waiting period under the Hart-Scott-Rodino Act expired on 18 September 2026, and Bio-Techne shareholders approved the takeover at a special meeting on 23 September 2026; completion is still expected in late 2026/early 2027 once the remaining clearances are in place (Bio-Techne release via BioSpace, 23 September 2026, https://www.biospace.com/press-releases/bio-techne-shareholders-approve-acquisition-by-merck-kgaa-darmstadt-germany). — Source: https://www.bundeskartellamt.de/SharedDocs/Meldung/DE/Pressemitteilungen/2026/08_17_26_BioTechne_MerckKGaA.html